The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Support side: New 13D filer — insiders or holders bought while this setup is live; see the timeline.
Radar 88 (high attention) · dilution pressure high · listing risk high · governance risk high · runway cash-flow positive · strongest signal: Auditor change (Jul 23, 2026)
What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (going concern in 8-k) coexists with live selling machinery (shelf effective, shelf filed). Base case is a discounted raise; the question is when, not if.
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25. Exchange deficiency plus a structural reason cure is hard (sub-$5M float, negative equity, no cash, or a reverse split already used). Under Nasdaq's 2026 rules (one reverse split per 12 months; $5M MVLS floor with no cure period from Sept 2026) the usual escape hatches are narrower.
The reported numbers themselves are in question — restatement, late filings or auditor churn. Treat the balance sheet with extra caution. A change of auditor or non-reliance on prior financials, together with late filings or a cluster of executive departures, is the pattern that precedes restatements, deregistration, or fraud allegations.
An activist has arrived at a company that needs cash — a potential catalyst, but any financing terms may favour the newcomer. A new active >5% holder appeared while the company is under cash or listing pressure - the classic precursor to a recapitalization, board change, or takeover at a discount.
BOXABL Inc. (formerly FG Merger II Corp.) closed its SPAC merger on July 17, 2026, converting from Nevada to Texas and issuing 246.5 million common shares plus 103.5 million preferred shares at a $3.5 billion valuation. On July 23, 2026, the company filed an 8-K (Item 3.01) disclosing receipt of a Nasdaq delisting notice and simultaneously disclosed an auditor change, officer departures, control changes, and material agreement terminations. Two separate Schedule 13D filings appeared July 24, 2026, indicating new activist holders crossing the 5% threshold. The company filed a $500 million S-3 shelf on July 27, 2026, which went effective August 10, 2026.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 138 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Aug 10, 2026 | ▼ Shelf effective | EFFECT notice 2026-08-10 filing | 21 |
| Aug 5, 2026 | ▼ Shelf filed | S-3/A filed 2026-08-05 filing | 32 |
| Jul 28, 2026 | ▼ Shelf filed | S-3/A filed 2026-07-28 filing | 35 |
| Jul 27, 2026 | ▼ Shelf filed | S-3 filed 2026-07-27 filing | 39 |
| Jul 24, 2026 | ▲ New 13D filer | Schedule 13D filed 2026-07-24 filing | 45 |
| Jul 24, 2026 | ▲ New 13D filer | Schedule 13D filed 2026-07-24 filing | 45 |
| Jul 23, 2026 | ▼ Auditor change | 8-K Item 4.01 filed 2026-07-23 (accepted 17:29 ET) filing | 62 |
| Jul 23, 2026 | ▼ Exchange deficiency notice | 8-K Item 3.01 filed 2026-07-23 (accepted 17:29 ET) filing | 60 |
| Jul 23, 2026 | ▼ Delisting language | “delisting notice” language in 8-K (8-K) filed 2026-07-23 filing | 46 |
| Jul 23, 2026 | · Change in control | 8-K Item 5.01 filed 2026-07-23 (accepted 17:29 ET) filing | 42 |
| Jul 23, 2026 | ▼ Unregistered sale | 8-K Item 3.02 filed 2026-07-23 (accepted 17:29 ET) filing | 41 |
| Jul 23, 2026 | ▼ Reverse split | “reverse split” language in 8-K (EX-10.4) filed 2026-07-23 filing | 37 |
| Jul 23, 2026 | ▼ Material agreement terminated | 8-K Item 1.02 filed 2026-07-23 (accepted 17:29 ET) filing | 35 |
| Jul 23, 2026 | ▼ Going concern in 8-K | “going concern 8k” language in 8-K (EX-99.2) filed 2026-07-23 filing | 31 |
| Jul 23, 2026 | ▼ Holder rights modified | 8-K Item 3.03 filed 2026-07-23 (accepted 17:29 ET) filing | 30 |
| Jul 23, 2026 | · Officer/director change | 8-K Item 5.02 filed 2026-07-23 (accepted 17:29 ET) filing | 28 |
| Mar 31, 2026 | ▼ Negative equity | Stockholders' equity $-44,933 as of 2026-03-31 filing | 31 |
VIVS VivoSim Labs, INC. · HCWB HCW Biologics Inc. · CYCU Cycurion, Inc. · BIAF bioAffinity Technologies, In · XHLD TEN Holdings, Inc. · VSEE VSEE HEALTH, INC. · screener →